Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of HIP1302 and HGP1406 (Tenofovir) in Healthy Volunteers
NCT02545829Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Aug 2015
- Primary completion
- Oct 2015
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HIP1302 in human immunodeficiency virus infection (HIV) and Chronic Hepatitis B (CHB) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Tenofovir Maximum Plasma Concentration at 72 hours and Tenofovir Area Under the Curve to Last Measurable Concentration at 72 hours. Started Aug 2015; status: completed.
02
Drugs
HIP1302
03
Conditions
human immunodeficiency virus infection (HIV)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02545829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545829.